SCHEMBL4072674

SCHEMBL4072674

CC(=O)c1ccc(-c2cc3ncnc(NCCc4c(C)[nH]c5c(F)ccc(C)c45)c3s2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 9/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TYK2 P29597 1/20 0.41
FLT1 P17948 4/20 0.38
EGFR P00533 4/20 0.36
MAP3K8 P41279 7/20 0.35
STK17A Q9UEE5 1/20 0.35
KDR P35968 1/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34
TUBA3E Q6PEY2 1/20 0.34
TUBA1A Q71U36 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068974 0.92 NPC1 (0.43) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL4068409 0.90 TYK2 (0.53) NPC1RAB9ATYK2FLT1EGFR
SCHEMBL3937751 0.90 NPC1 (0.46) NPC1RAB9ATYK2FLT1EGFR
SCHEMBL3939022 0.89 NPC1 (0.45) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL3930368 0.89 NPC1 (0.45) NPC1RAB9ATYK2FLT1EGFR
SCHEMBL4065656 0.88 FLT1 (0.45) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL4071195 0.88 FLT1 (0.46) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL3936128 0.88 NPC1 (0.43) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL4073363 0.88 NPC1 (0.43) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL4069307 0.88 NPC1 (0.46) STK17BNPC1RAB9ATYK2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 STK17B 3100/4885NPC1 2246/4885RAB9A 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.